BACKGROUND
==========

Gene/gene variants
------------------

The peroxisome proliferator-activated receptors (PPAR-α, PPAR-δ, and PPAR-γ) are transcription factors belonging to the nuclear hormone receptor superfamily ([@bib1]). These receptors combine with the retinoid X receptors to form heterodimers that regulate various genes involved in lipid and glucose metabolism, fatty acid transport, adipocyte differentiation, carcinogenesis, and inflammation ([@bib2]--[@bib4]). Here we consider the relation between the peroxisome proliferator-activated receptor-γ2 (*PPARG2*) gene and type 2 diabetes.

The *PPARG* gene is located on chromosome 3p25 (OMIM number 601487) and encodes a nuclear transcription factor involved in the expression of hundreds of genes. The *PPARG* gene contains 9 exons, spans more than 100 kilobases, and, because of alternative mRNA splicing, results in the production of 2 protein isoforms, PPARG1 and PPARG2 ([@bib5]). *PPARG1* is encoded by 8 exons, using exons 1--6, A1, and A2, with *PPARG2* being encoded using exons 1--6 and B. While PPARG1 is found ubiquitously in the body, PPARG2 is largely found in adipose tissue and the large intestine ([@bib5]). Several variants in the *PPARG* gene have been identified, with the Pro12Ala variant having been the most extensively examined in epidemiologic studies. The *PPARG* gene locus and gene variants have previously been addressed in a Human Genome Epidemiology (HuGE) review on the genetics of leptin and obesity ([@bib6]). The association between the Pro12Ala variant (rs1801282) and type 2 diabetes has been the focus of several meta-analyses ([Table 1](#tbl1){ref-type="table"}).

###### 

Findings From Previously Conducted Meta-Analyses of the Peroxisome Proliferator-Activated Receptor-γ2 (*PPARG2*) Pro12Ala Gene Variant and Type 2 Diabetes, 2000--2007

  Study and Year (Ref.)                Study Details                                                                                                    No. of Studies   No. of Cases   No. of Controls   Main Analyses                           Subanalyses                                                                                            
  ------------------------------------ ---------------------------------------------------------------------------------------------------------------- ---------------- -------------- ----------------- --------------------------------------- --------------------------------------------- ------------------------------------------------- ------ ------------
  Altshuler et al., 2000 ([@bib30])    Very little detail presented.                                                                                    8                NS             NS                0.79                                    0.70, 0.89[a](#tblfn1){ref-type="table-fn"}   NS                                                       
  Ek et al., 2001 ([@bib31])           Meta-analysis (using Mantel-Haenszel method) of published case-control studies.                                  10               3,032          3,812             0.81                                    0.72. 0.91                                    Caucasian participants                            0.85   0.76, 0.96
                                                                                                                                                                                                                                                                                                East Asian participants                           0.42   0.26, 0.67
  Lohmueller et al., 2003 ([@bib34])   Meta-analysis (using both fixed-effect and random-effects methods) of published case-control studies.            14               NS             NS                1.22[b](#tblfn2){ref-type="table-fn"}   1.08, 1.37                                    Random effects[b](#tblfn2){ref-type="table-fn"}   1.21   1.07, 1.37
  Hara et al., 2003 ([@bib33])         Meta-analysis in a Japanese publication.                                                                         8                NS             NS                0.81[c](#tblfn3){ref-type="table-fn"}   0.78, 0.93[c](#tblfn3){ref-type="table-fn"}   NS                                                       
  Parikh and Groop, 2004 ([@bib35])    Meta-analysis (using Mantel-Haenszel method) of published studies.                                               23               NS             NS                0.79                                    NS                                            NS                                                       
  Vardarli, 2007 ([@bib32])            Abstract of meta-analysis (using DerSimonian and Laird ([@bib24]) random-effects method) of published studies.   33               14,771         14,513            0.86                                    0.75, 0.97                                    NS                                                       
  Ludovico et al., 2007 ([@bib29])     Meta-analysis (using random-effects method and dominant genetic model) of published and unpublished studies.     43               19,250         23,660            0.81                                    0.75, 0.88                                    East Asian participants                           0.65   0.54, 0.79
  North American participants          0.82                                                                                                             0.67, 1.01                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                European participants                             0.86   0.79, 0.95
                                                                                                                                                                                                                                                                                                    Northern Europeans                            0.74   0.66, 0.83
                                                                                                                                                                                                                                                                                                    Central Europeans                             0.90   0.82, 1.00
                                                                                                                                                                                                                                                                                                    Southern Europeans                            1.01   0.80, 1.28

Abbreviations: CI, confidence interval; NS, not stated; OR, odds ratio.

The 95% CI was estimated using the *P* value (*P* = 0.0007) from the paper by Altshuler et al. ([@bib30]).

The risk allele was defined as Pro12.

The OR and 95% CI were estimated from Figure 9 in the paper by Hara et al. ([@bib33]).

Gene variant frequency
----------------------

Yen et al. ([@bib7]) first identified a missense mutation resulting in the alanine substitution for proline at codon 12 of the *PPARG* gene. The frequency of the 12Ala allele has been found to range from 2% to 18% in healthy people ([@bib6]). We estimated Pro12Ala allele frequencies from the control groups of all studies identified for inclusion in the present review (see [Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1), which is posted on the *Journal*'s Web site (<http://aje.oxfordjournals.org/>)). Across all studies, the frequency of the 12Ala allele in control groups ranged from 1.7% to 21.6% (median, 9.5%). In the studies reporting controls as ethnically Caucasian, the 12Ala allele frequency ranged from 5.9% to 21.6% (median, 12.7%). In studies reporting controls as ethnically of East Asian descent (such as Chinese or Japanese), the 12Ala allele frequency ranged from 1.7% to 9.3% (median, 4.5%).

Disease
-------

By the year 2030, diabetes mellitus is expected to affect almost 5% of the world\'s population---an estimated 366 million people ([@bib8]). The vast majority of these cases will be type 2 diabetes, with current diagnoses currently accounting for approximately 90%--95% of diabetes cases. Diabetes prevalence is currently about 3% in the general population, with increased prevalence in some ethnic minority groups (such as South Asians, Africans, Afro-Caribbeans, and Chinese), as well as in less affluent populations, including those that are less physically active, have central obesity, and have a high body mass index (BMI; weight (kg)/height (m)^2^). Some populations, such as Pima Indians, Australian Aboriginal communities, and Pacific and Indian Ocean Islanders, have a far higher prevalence, at up to 40% ([@bib9]). The presence of diabetes mellitus is associated with a range of vascular complications (such as myocardial infarction, stroke, heart failure, renal failure, angina, and retinopathy) leading to a reduced life expectancy and a reduced quality of life ([@bib10]). The large and increasing burden of type 2 diabetes and the potential for modifying risk through adequate treatments and lifestyle alterations make the identification of methods for the early detection of persons at greater risk an important public health challenge.

Knowledge of genetic polymorphisms that allow accurate quantification of type 2 diabetes risk will allow the development of complex models with diagnostic and prognostic potential. Several extensive reviews have summarized findings on the genetic epidemiology of type 2 diabetes ([@bib11]--[@bib13]). However, substantial advances have been made in the past few years, with an increase in confirmed type 2 diabetes susceptibility loci from 3 genes (*PPARG*, *KCNJ11*, and *TCF7L2*) to almost 20 (with newly identified variants in the following genes: *ADAMTS9*, *CDKAL1*, *CDKN2A/B*, *CAMK1D*, *FTO*, *HHEX/IDE*, *HNF1B*, *IGF2BP2*, *JAZF1*, *MTNR1B*, *NOTCH2*, *SLC30A8*, *THADA*, *TSPAN8*, and *WFS1*) ([@bib14]--[@bib17]). This major step forward has been due mainly to advances in technology, with genome-wide association scans now allowing unprecedented progress to be made in the understanding of the genetic etiology of several complex diseases, including type 2 diabetes. It is increasingly evident that the genetic basis of type 2 diabetes involves multiple genes that each have a modest effect size on diabetes susceptibility and that interaction with other susceptibility loci and/or environmental factors may result in more substantial effects.

Objectives
----------

The association between the *PPARG2* Pro12Ala gene variant and type 2 diabetes has been investigated in numerous epidemiologic studies since it was first suggested in 1998 that carriers of the 12Ala variant showed a 75% reduction in risk of type 2 diabetes (see [Web reference 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (W1), which is listed in [Web Appendix 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) on the *Journal*'s Web site (<http://aje.oxfordjournals.org/>)). Here we evaluate the evidence for an association between the *PPARG2* Pro12Ala (rs1801282) gene variant and type 2 diabetes using methods developed by the Human Genome Epidemiology Network and the Cochrane Collaboration ([@bib18]--[@bib20]). We report results from an updated meta-analysis of 60 association studies, involving a total of 32,849 type 2 diabetes cases and 47,456 controls in relation to the Pro12Ala gene variant in the *PPARG* gene. The present report primarily focuses on population association studies (including case-control, cohort, and genome-wide association studies but excluding family-based studies) and contains an investigation of potential sources of heterogeneity.

MATERIALS AND METHODS
=====================

Selection criteria and identification of studies
------------------------------------------------

Eligible for inclusion were all population-based cohort, case-control, or cross-sectional studies reporting on associations between the *PPARG2* Pro12Ala variant and type 2 diabetes. We performed electronic searches, not limited to the English language, of Medline (using PubMed), EMBASE, HuGE Navigator, Web of Science, and the Science Citation Index using the search method described in [Web Appendix 2](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>). The latest searches were undertaken on September 14, 2009. All relevant articles identified through the search were scanned on the basis of title, keywords, and abstract (where available) by one of us and were rejected in the initial screening if the article clearly did not meet the inclusion criteria. Where a title/abstract could not be rejected with certainty, we obtained the full text of the article for evaluation. We also reviewed the reference lists of retrieved articles to identify other relevant publications.

In addition, we searched specifically for genome-wide association studies of type 2 diabetes using the catalog of published genome-wide association studies ([@bib21]). The latest searches were undertaken on September 14, 2009. The full text and any supplementary materials were collected for each study identified. Data for the Pro12Ala single nucleotide polymorphism (SNP) (rs1801282) were extracted from each report, and study authors were contacted if insufficient data were reported.

Data collection
---------------

The following data were extracted independently by at least 2 investigators, using a piloted data extraction form (with any discrepancies being resolved by discussion and, when necessary, adjudicated by a third reviewer): genotype frequencies by case/control status; mean ages of cases and controls; proportions of males and ethnic subgroups (defined as people of European continental ancestry, East Asian ancestry, or other); genotyping methods; and blinding of laboratory workers to participant case/control status. We calculated allele frequencies from control groups of studies that presented data on all 3 genotype groups, assuming Hardy-Weinberg equilibrium where appropriate. Where there were multiple publications from the same study group, we extracted data from each report and selected only the most complete and up-to-date data. When articles presented data for different ethnic groups or different case or control sources, results for the subgroups were considered as separate studies. Where data could not be extracted for inclusion in the meta-analysis, the investigators were contacted via letter and e-mail. Selected articles also included 4 Chinese-language publications, from which data were available from the English-language abstract (W2--W5).

Data analysis
-------------

The primary analyses for which results are presented were conducted using a per-allele inheritance model. This was the model favored by an initial analysis using the inheritance-model-free analysis of Minelli et al. ([@bib22]) (data not shown). We estimated the per-allele odds ratio using logistic regression within each study. We used funnel plots and associated tests to assess assumptions involved in meta-analysis and to explore the relation between precision and magnitude of association ([@bib23]). The meta-analyses used a standard approach, weighting by precision and incorporating random effects to allow for the variation in true associations across studies ([@bib24]). We performed a cumulative meta-analysis to demonstrate how evidence concerning the genetic association has evolved over time.

Consistency of the gene effect sizes across studies was assessed using a test for heterogeneity and the *I*^2^ statistic, which describes the percentage of total variation in point estimates attributable to genuine variation rather than sampling error ([@bib25]). We further explored this variation by prespecified subgrouping of studies according to sample size (\<100, 100--499, or ≥500), ethnicity (Caucasian or East Asian), source of controls (general population or hospital), study design (retrospective or prospective), and blinding of genotyping to clinical outcome (yes, no, or unknown). We used random-effects meta-regression to explore the extent to which these subgroups could explain the between-study variance. Fixed-effect meta-analyses were conducted as sensitivity analyses. All ranges presented are 95% confidence intervals unless otherwise specified.

Only summary meta-analysis results were available from Zeggini et al. ([@bib26]). Their analysis used imputed and genotyped data for the *SYN2*/*PPARG* region, including either the rs17036101 SNP or the rs1801282 SNP, as these 2 SNPs represent the same association signal. Using the rs17036101 SNP as a proxy for rs1801282, we combined a random-effects meta-analysis result from Zeggini et al. ([@bib26]) with a random-effects meta-analysis of nonoverlapping studies from our own searches. We first computed the summary log odds ratio and its variance for each data source and then computed the total sum of weights and the total sum of (weight × log odds ratios) across both sources, and used these to produce an overall summary estimate and variance. This is equivalent to a standard random-effects meta-analysis, with the exception that an estimate of between-study variance among Zeggini et al.'s ([@bib26]) studies is used in the weights for those studies and an estimate of between-study variance among our studies is used in the weights for our studies.

RESULTS
=======

Characteristics of the included studies
---------------------------------------

Our literature searches yielded 1,734 reports, from which 74 eligible studies were identified, in addition to 30 genome-wide association studies (W1--W85) ([Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) and [Tables 2](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) and [3](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1)). Sixty-six studies ([Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1)) contributed to the present review (W1--W7, W9--W14, W17, W19--W21, W23, W25, W27--W34, W36, W37, W40--W45, W47--W54, W56, W59, W61, W63, W65, W67, W68, W70, W72, W74, W79, W80, W83, W85). Nine studies from 7 papers (W35, W46, W55, W57, W77, W78, W81) (comprising approximately 7% of eligible cases and 10% of eligible controls) could not be included because of insufficient detail and lack of response from authors after our attempts at correspondence ([Table 2](#tbl2){ref-type="table"}). Researchers from the European Prospective Investigation Into Cancer and Nutrition (EPIC) provided unpublished data. Study-level characteristics for the EPIC study ([@bib27]) and the EPIC nested case-control data have been previously published (supplementary materials of Zeggini et al. ([@bib26])); summary details are available in [Web Table 2](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>) and [Web Appendix 3](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>). We also identified 30 genome-wide association studies of type 2 diabetes in 16 papers published since 2007 (W18, W22, W24, W26, W58, W60, W62, W64, W66, W69, W71, W73, W75, W76, W82, W84) (see [Table 3](#tbl3){ref-type="table"} and [Web Table 3](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>)). Each of these studies included either the Pro12Ala variant (rs1801282) or a nearby tagging SNP. Zeggini et al. ([@bib26]) presented results from a meta-analysis of 59,682 participants across several of these genome-wide association studies (W62, W64, W73, W84).

###### 

Characteristics of Genetic Association Studies of the Peroxisome Proliferator-Activated Receptor-γ2 (*PPARG2*) Pro12Ala Gene Variant and Type 2 Diabetes That Were Potentially Eligible for Inclusion in the Current Analysis but Did Not Have Full Genotype Data Available, 2000--2006

  Study and Year (Ref.)             No. of Cases   No. of Controls   \% Male   Mean Age, years (SD)   Diagnostic Criteria   Molecular Technique   HWE Testing   Control Source   Study Design   Ethnicity/Geographic Location                                 
  --------------------------------- -------------- ----------------- --------- ---------------------- --------------------- --------------------- ------------- ---------------- -------------- ------------------------------- ----------------------------- ----------------------------
  Li, 2000 (W35)                    17             138               0.0       0.0                    NS                    NS                    NS            Probes           In HWE         Extremely obese participants    C-C                           Caucasian/United States
  Mirzaei et al., 2009 (W46)        NS             NS                NS        NS                     NS                    NS                    NS            NS               NS             NS                              C-C                           Caucasian/Iranian
  Poulsen et al., 2003 (W55)        32             188               NS        NS                     NS                    NS                    NS            RFLP             In HWE         Population-based twin study     Population-based twin study   Caucasian/Denmark
  Radha et al. (A), 2006 (W57)      799            820               43.6      36.5                   52 (11)               41 (13)               WHO           RFLP             In HWE         GP                              C-C                           South Asian/India
  Radha et al. (B), 2006 (W57)      81             616               56.8      58.9                   56 (10)               42 (13)               WHO           RFLP             In HWE         GP                              C-C                           South Asian/India
  Radha et al. (C), 2006 (W57)      123            334               71.5      50.3                   59 (8)                37 (14)               WHO           RFLP             In HWE         GP                              C-C                           Caucasian/United States
  Vieira-Filho et al., 2004 (W77)   NS             NS                NS        NS                     NS                    NS                    WHO           RFLP             In HWE         GP                              Cohort                        Parkataje Indian/Brazil
  Wakil et al., 2006 (W78)          1,137          219               NS        NS                     NS                    NS                    WHO           Probes           NS             GP---normal glucose tolerance   C-C                           Saudi Arabian/Saudi Arabia
  Yanagisawa et al., 2001 (W81)     NS             NS                NS        NS                     NS                    NS                    WHO           RFLP             NS             GP                              Cohort                        Palauan/Palau

Abbreviations: C-C, case-control; GP, general population; HWE, Hardy-Weinberg equilibrium; NS, not stated; RFLP, restriction fragment length polymorphism; SD, standard deviation; WHO, World Health Organization.

###### 

Characteristics of the Genome-Wide Association Studies Conducted for Type 2 Diabetes, 2007--2009

  Study and Year (Ref.)                                                                 Ethnicity/Location               Cases                 Controls                                                                                                                                                                          
  ------------------------------------------------------------------------------------- -------------------------------- --------------------- --------------------- ------- ----------------------- --------------------- ------------------------------------------------------ ------- ------- ------- ---------------------- ----------------------
  Takeuchi et al., 2009 (W71)                                                           Japan                            1,629                 928                   701     NS                      Stage 1: 66.6 (9.8)   Stage 1: 24.5 (3.6)                                    1,517   806     711     Stage 1: 64.7 (6.8)    Stage 1: 23.3 (3.1)
  Stage 2: 62.7 (11.7)                                                                  Stage 2: 23.3 (3.9)              Stage 2: 71.1 (9.6)   Stage 2: 23.0 (3.1)                                                                                                                                                               
  Timpson et al., 2009 (W75)---see Zeggini et al., 2007 (W75)                           United Kingdom                                                                                                                                                                                                                           
  Herder et al., 2008 (W26)                                                             Germany                          433                   255                   178     NS                      65.2 (8.3)            30.9 (5)                                               1,438   693     745     61.9 (10.2)            27.7 (4.3)
  Unoki et al. (A), 2008 (W76)                                                          Japan                            5,149                 3,112                 2,037   NS                                                                                                   4,176   1,988   2,188                          
  Unoki et al. (B), 2008 (W76)                                                          Singapore                        1,498                 736                   762     NS                      63.9 (9.7)            25.3 (3.9)                                             1,881   828     1,053   35.4 (11.2)            22 (3.4)
  Unoki et al. (C), 2008 (W76)                                                          Denmark                          4,085                 2,423                 1,662   NS                      60 (9.8)              30.6 (5.6                                              5,302   2,456   2,846   46.9 (9.1)             25.6 (4)
  Yasuda et al., 2008 (W82)                                                             Japan                                                                                                                                                                                                                                    
  Sladek et al., 2007 (W66)---initial sample set                                        France                           1,380                 838                   542     45.0 (8.4)              60.0 (10.3)           25.8 (2.8)                                             1,323   532     791     53.4 (5.6)             23.2 (1.8)
  Sladek et al., 2007 (W66)---replication sample set                                    France                           2,617                 1,628                 989     50.4 (11.0)             62.2 (11.0)           28.9 (3.6)                                             2,894   1,240   1,654   56.4 (10.2)            25.3 (3.5)
  Zeggini et al., 2007 (W84)---initial sample set                                       United Kingdom                   1,924                 1,118                 806     50.3 (9.2)              58.6 (10.1)           NS                                                     2,938   1,446   1,492   NS                     NS
  Zeggini et al., 2007 (W84)---replication sample set                                   United Kingdom                   3,757                 2,137                 1,620   54.3 (9.4)              63.1 (9.7)            NS                                                     5,346   2,719   2,627   49.9 (16.4)            NS
  Steinthorsdottir et al., 2007 (W69)---initial sample set                              Iceland                          1,399                 832                   567     56.2 (12.3)             64.4 (12.8)           56.2 (12.3) \[688\][b](#tblfn5){ref-type="table-fn"}   5,275   2,743   2,532   58.3 (17.4)            27.1 (4.9) \[1,751\]
  Steinthorsdottir et al., 2007 (W69)---replication sample set                          Denmark                          1,359                 821                   538     52.1 (10.3) \[1,013\]   56.8 (10.5)           29.7 (5.3) \[1,343\]                                   4,825   2,249   2,576   46.4 (8.8)             25.5 (4.1) \[4,824\]
  Scott et al., 2007 (W64)---initial sample set                                         Finland                          1,161                 653                   508     53                      63.4                  29.8                                                   1,174   574     600     64                     26.8
  Scott et al., 2007 (W64)---replication sample set                                     Finland                          1,215                 724                   491     56                      60                    30.1                                                   1,258   768     490     59                     26.4
  Saxena et al., 2007 (W62)---initial sample set                                        Finland                          1,007                 513                   494     55.5 (9.7) \[946\]      63.4 (9.9)            28.8 (4.6) \[998\]                                     1,038   498     540     59.0 (10.2)            26.8 (3.8) \[1,032\]
  Saxena et al., 2007 (W62)---initial sample set                                        Sweden                           457                   228                   229     59.9 (10.7)             66.0 (10.7)           28.0 (4.2)                                             429     209     220     58.3 (9.9)             26.4 (3.7) \[420\]
  Saxena et al., 2007 (W62)---replication sample set                                    Sweden                           2,830                 1,667                 1,163   NS                      59.0 (12.0)           29.6 (5.5)                                             3,550   1,340   2,210   57.0 (6.0)             25.1 (3.6)
  Saxena et al., 2007 (W62)---replication sample set                                    European descent/United States   1,226                 644                   582     NS                      63.0 (11.0)           32.9 (6.9)                                             1,226   644     582     61.0 (10.0)            27.4 (5.2)
  Saxena et al., 2007 (W62)---replication sample set                                    Poland                           1,009                 422                   587     NS                      62.0 (10)             29.6 (4.8)                                             1,009   422     587     59.0 (7.0)             26.1 (3.6)
  Wellcome Trust Case-Control Consortium, 2007 (W73)---see Zeggini et al., 2007 (W73)   United Kingdom                   1,924                                                                                                                                                    2,938                                          
  Salonen et al., 2007 (W60)---initial sample set                                       White/European                   500                   228                   272     NS                      NS                    NS                                                     497     NS      NS      NS                     NS
  Salonen et al., 2007 (W60)---replication sample set                                   White/European                   2,573                 NS                    NS      NS                      NS                    NS                                                     2,776   NS      NS      NS                     NS
  Rampersaud et al., 2007 (W58)---initial sample set                                    Amish/United States              124                   41                    83      NS                      51.3 (10.5)           29.3 (5.8)                                             295     153     142     64.4 (12.9)            27.4 (4.7)
  Rampersaud et al., 2007 (W58)---replication sample set                                Amish/United States                                                                                                                                                                       427     200     227     51.9 (11.9)            27.7 (5.0)
  Hayes et al., 2007 (W24)                                                              Mexican-American                 281                   108                   173     45.9 (10.1)             57.9 (10.7)           31.5 (6.2)                                             280     69      211     NS                     NS
  Hanson et al., 2007 (W22)---initial sample set                                        American Indian                  300                   114                   186     19.2 (4.5)              NS                    38.9 (8.4)                                             334     160     174     55.5 (9.8)             35.4 (8.0)
  Hanson et al., 2007 (W22)---replication sample set                                    American Indian                  1,207                 459                   748     39.7 (10.6)             NS                    38.3 (8.2)                                             1,627   748     879     27.7 (11.6)            35.6 (8.2)
  Florez et al., 2007 (W18)---initial sample set                                        United States                    91                    NS                    NS      NS                      NS                    NS                                                     1,087   527     560     51.5 (9.8) \[1,032\]   27.5 (5.2) \[1,026\]
  Florez et al., 2007 (W18)---replication sample set                                    United States                    158                   NS                    NS      NS                      NS                    NS                                                     1,465   691     774     56.1 (9.3) \[1,390\]   27.4 (4.8) \[1,384\]

Abbreviations: BMI, body mass index; NS, not stated; SD, standard deviation.

Weight (kg)/height (m)^2^.

Numbers in brackets, number of subjects.

The identified studies were published between 1998 and 2008 and were undertaken in a wide range of geographic settings, with 66% (21,670 of 32,849) of cases having white European continental ancestry (Caucasian), 25% (8,187 of 32,849) being East Asian, and 9% (2,992 of 32,849) having other ethnic origins (including African-American, American Indian, or not stated). Nine studies were described as prospective in design, 3 were described as cross-sectional studies, 8 as genome-wide association studies, and 47 as case-control studies. Thirty-one studies involved general population-based controls, 4 involved hospital-based controls, and 1 involved health-care employees; in 13 studies, investigators did not describe the source of their controls (see [Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1)). In 32 studies, authors reported using World Health Organization criteria for diagnosis of type 2 diabetes ([@bib28]). Restriction fragment length polymorphism analysis was the most common method of genotyping used. In 23 studies, authors did not report any information on the BMI of the case group (see [Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1)). In 11 studies, investigators reported information regarding age at disease onset. Of the 67 included studies, 60 provided data for the per-allele genetic model in our presented analyses (W1--W4, W6, W7, W9--W14, W17--W21, W25--W33, W36, W37, W40--W45, W47--W50, W52--W54, W56, W59, W61, W63--W65, W67, W71, W74, W84, W85).

Two studies were found to deviate from Hardy-Weinberg equilibrium according to the test *P* value (*P* \< 0.05) (W2, W5). Approximately 70% of the studies had fixation coefficients with absolute values larger than 0.03 (median, −0.004; range, −0.072 to 0.185), with the studies evenly distributed around zero. Authors in 42 studies reported testing for Hardy-Weinberg equilibrium and found no deviation (see [Web Table 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) and [Table 2](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1)).

Associations
------------

In a random-effects meta-analysis with a per-allele genetic model, the combined type 2 diabetes odds ratio for the Pro12Ala polymorphism across the 66 studies was 0.86 (95% confidence interval (CI): 0.81, 0.90) ([Web Figure 1](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>)). The fixed-effect meta-analysis was 0.85 (95% CI: 0.82, 0.88). The cumulative meta-analysis illustrates the exaggerated effect often observed in the earliest study and reveals that the accumulated evidence hovered around the conventional 5% significance level until 2004. In studies published between 2004 and 2008, the overall *P* value was reduced from 0.028 to 1.3 × 10^−8^.

![Results from random-effects meta-analyses of studies of the peroxisome proliferator-activated receptor-γ2 (*PPARG2*) Pro12Ala gene variant and type 2 diabetes according to various study-level characteristics. BMI, body mass index (weight (kg)/height (m)^2^); CI, confidence interval; GWA, genome-wide association.](amjepidkwp450f01_ht){#fig1}

There was evidence of a moderate degree of inconsistency among these studies (*I*^2^ = 37%, 95% CI: 9, 54; *P* = 0.0028), and no evidence of funnel plot asymmetry was found either visually or using the Harbord test ([@bib23]) (*P* = 0.87). Study participant ethnicity accounted for some of this heterogeneity (14% of the between-study variance). Results from subgroup analyses are presented in [Figure 1](#fig1){ref-type="fig"}. When we considered only the large (\>500 cases) studies, the odds ratio was 0.84 (95% CI: 0.79, 0.90), with *I*^2^ = 43% (95% CI: 0, 66; *P* = 0.025). When studies were subgrouped by ethnicity, the odds ratio was nearer 1 for Caucasians (odds ratio = 0.86 (95% CI: 0.81, 0.90), *I*^2^ = 37% (95% CI: 0, 57; *P* = 0.019)) than for East Asians (odds ratio = 0.78 (95% CI: 0.65, 0.99), *I*^2^ = 45% (95% CI: 0, 69; *P* = 0.031)), although the difference was not statistically significant (*P* = 0.38). A dominant analysis of all studies composed of Asian populations produced an odds ratio of 0.80 (95% CI: 0.66, 0.97), with *I*^2^ = 40.5% (95% CI: 0, 64).

The combined odds ratio for studies with a mean case BMI less than 25 was 0.88 (95% CI: 0.68, 1.13), with *I*^2^ = 57% (95% CI: 0, 78; *P* = 0.016). Studies with a mean case BMI between 25 and 29.9 had an odds ratio of 0.84 (95% CI: 0.77, 0.91), with *I*^2^ = 0% (95% CI: 0, 47; *P* = 0.45). Studies with a mean case BMI greater than or equal to 30 had an odds ratio of 0.90 (95% CI: 0.82, 0.99), with *I*^2^ = 46% (95% CI: 0, 68; *P* = 0.024). A test for trend across these 3 groups was not statistically significant (*P* = 0.49).

No statistically significant differences were observed according to study design. Forty case-control studies had an odds ratio of 0.85 (95% CI: 0.79, 0.92), with *I*^2^ = 44%; 9 prospective studies had an odds ratio of 0.88 (95% CI: 0.74, 1.04), with *I*^2^ = 35%; and the 8 genome-wide association studies had an odds ratio of 0.84 (95% CI: 0.79, 0.89), with *I*^2^ = 0%. Only 3 cross-sectional studies were available. Only in 10 studies did authors report blinding, and among those studies that did not report blinding status, the pooled odds ratio was 0.86 (95% CI: 0.77, 0.97), with *I*^2^ = 63.

We also investigated potential variation arising from the use of different sources of controls. In 42 studies, investigators reported the use of a general population cohort as their control group; the combined odds ratio was 0.86 (95% CI: 0.81, 0.91), with *I*^2^ = 38%. In only 4 studies did authors report the use of hospital-based controls; in those studies, the odds ratio was 1.09 (95% CI: 0.86, 1.37), with *I*^2^ = 0% (*P* = 0.06 in comparison with general population controls), while in those studies for which authors did not state the source of their controls (*n* = 11), the pooled odds ratio was 0.77 (95% CI: 0.64, 0.93), with *I*^2^ = 21.1% (*P* = 0.26 in comparison with general population controls).

We combined the random-effects meta-analysis of Zeggini et al. ([@bib26]) with our own random-effects meta-analysis of nonoverlapping published literature-based studies to produce an overall pooled odds ratio of 0.88 (95% CI: 0.84, 0.92) involving a total of 116,040 participants (see [Figure 1](#fig1){ref-type="fig"}).

DISCUSSION
==========

Main findings
-------------

This HuGE association review involved an updated meta-analysis of the relation between the *PPARG* Pro12Ala polymorphism and type 2 diabetes among 32,849 cases and 47,456 controls in 60 studies (counting every study\'s cases and controls only once). The *PPARG* 12Ala polymorphism was associated with a reduction in type 2 diabetes risk (odds ratio = 0.86, 95% CI: 0.81, 0.90), and this confirms findings from previous meta-analyses ([@bib29]--[@bib35]). When only the largest studies (\>500 cases) were considered, the association remained stable (odds ratio = 0.84, 95% CI: 0.79, 0.90). This work further confirms the association between the *PPARG* Pro12Ala polymorphism and type 2 diabetes.

The results of the Zeggini et al. ([@bib26]) meta-analysis of genome-wide association studies were compatible with our own literature-based meta-analysis. The Zeggini et al. analysis provided an estimate that minimized publication bias because of the availability of genotype data from a consortium-based approach. We pooled this estimate with our own estimate from nonoverlapping published literature association studies to produce an estimate for 116,040 participants. Proposed guidelines for assessing the strength of evidence from gene-disease association studies ([@bib36]) would designate the findings for Pro12Ala and type 2 diabetes as "strong" evidence (see [Web Table 4](http://aje.oxfordjournals.org/cgi/content/full/kwp450/DC1) (<http://aje.oxfordjournals.org/>)).

Limitations
-----------

When interpreting these results, the potential limitations of such a report should be considered. First, the key threat to any literature-based review and meta-analysis is that of reporting bias (where only the most exciting findings are available in the published literature). Although our own assessments did not generally suggest the presence of material publication bias, it is not possible to rule it out entirely ([@bib37], [@bib38]). Given the consistency of findings between our main analysis and our analysis of only the large (\>500 cases) studies, which should have been less prone to selective reporting, we may place reasonable confidence in our observations. Our findings were also consistent with the results from Zeggini et al.'s meta-analysis of genome-wide association studies ([@bib26]).

Consistency across studies
--------------------------

Overall, *I*^2^ was estimated to be 37%, with statistically significant evidence of heterogeneity. This represents a moderate level of inconsistency attributable to genuine variation in gene effect size. It has been hypothesized in the past that this may reflect variation between ethnic populations. We observed a slightly higher magnitude of association in East Asians compared with Caucasians, but the difference was not statistically significant. Polymorphism frequencies are known to vary by ethnicity, but the effect of this on risk remains insufficiently studied. In the studies we identified, the frequency of the 12Ala polymorphism in controls was observed to be greater in Caucasian populations than in East Asian populations.

The observed difference in the magnitude of association between these populations may also be explained partly by differences in BMI. In a study of French Caucasians conducted by Ghoussaini et al. (W20), the presence of the Pro12 variant was observed to double the risk of type 2 diabetes in the obese subpopulation. However, the Ala12 variant has also been shown to be weakly associated with higher BMI, as confirmed in a meta-analysis conducted in 2003 by Masud et al. ([@bib39]).

A meta-analysis conducted by Ludovico et al. (W37) found that the alanine polymorphism conferred significantly greater protection against type 2 diabetes among Asians than among Caucasians. Using 10 studies of Asian populations, their results revealed an odds ratio of 0.65 (95% CI: 0.54, 0.79). When the analysis was adjusted for BMI in the controls, this statistical significance was lost. Furthermore, taking into account body fat content and distribution, Radha et al. (W57) found no protective effect of the Pro12Ala polymorphism in South Asians.

We conducted a similar analysis of results from 20 relevant studies (using a dominant model) which showed an odds ratio of 0.80 (95% CI: 0.66, 0.97) and suggested no difference between Asians and Caucasians (*P* = 0.59). Studies in which cases had a lower mean BMI observed a slightly greater protective effect of the 12Ala polymorphism on type 2 diabetes risk, but this was not statistically significant (*P* = 0.57; see also [Figure 1](#fig1){ref-type="fig"}).

In 2001, Luan et al. ([@bib40]) hypothesized a gene-nutrient interaction based on the ratio of polyunsaturated fats to saturated fats which determined the association between the Pro12Ala polymorphism and BMI. This study may contribute towards an explanation of the role played by ethnicity and differences in dietary habits. However, more recently, Robitaille et al. ([@bib41]) suggested an interaction in the opposite direction, highlighting the need to carefully assess possible interactions.

Another potential source of variation has been identified by Hegele et al. (W25) and Radha et al. (W57): These authors noted differences in the association between Pro12Ala and type 2 diabetes between men and women. More recently, Ali et al. (W1), Morini et al. ([@bib42]), and Mattevi et al. ([@bib43]) observed a relation between the polymorphism and higher BMI in men which was absent in women. Since few investigators publish their data stratified by sex, we were unable to investigate these issues in detail. Although these investigations have been inconsistent in the past, differences in the phenotypic consequences of the Pro12Ala polymorphism among males and females warrant further investigation. Further studies of gene-gene and gene-environment interaction are necessary to better understand these relations.

Biology
-------

The substitution from proline to alanine at codon 12 has been found to modulate transcriptional activity ([@bib44], [@bib45]). This substitution is close to the NH~2~-terminus of the protein in the ligand-independent activation domain, the activity of which is potentiated through phosphorylation by insulin. The structure and consequently the function of the protein may be affected by this amino acid change, since alanine favors the formation of α-helices while proline prevents it ([@bib46]). The alanine isoform leads to the less efficient stimulation of PPARG target genes and predisposes people to lower levels of adipose tissue mass accumulation, which in turn may improve insulin sensitivity---thus supporting the protective effect observed for 12Ala carriers, since decreased insulin sensitivity plays a central role in the pathogenesis of type 2 diabetes.

Potential public health impact and other implications of results
----------------------------------------------------------------

There is evidence that *PPARG* supports the "thrifty gene hypothesis" in that the wild-type genotype optimizes the building of fat deposits as energy reserves and thus favored human survival in times when food was either limited, sporadically available, or poor in quality ([@bib47]--[@bib50]). Because today\'s lifestyle is much more relaxed and sedentary and is characterized by a diet that is rich in carbohydrates and fats and poor in fiber, these once favorable genetic factors have now become detrimental, leading to an increase in the risk of developing chronic diseases such as type 2 diabetes. PPARG is a known target for thiazolidinediones, antidiabetic drugs which have been shown to improve insulin sensitivity and to reduce plasma glucose and blood pressure in persons with type 2 diabetes ([@bib51]). Thiazolidinediones are highly specific ligands for PPARG and lead to the activation of the nuclear receptor on binding ([@bib52]).

Since the Pro12 allele is present in at least 80% of humans, the population attributable risk of type 2 diabetes associated with this polymorphism is as high as 25% ([@bib30]). This gene is a confirmed type 2 diabetes susceptibility locus and is now one of almost 20 type 2 diabetes susceptibility loci identified over the last few years. With other type 2 diabetes susceptibility loci, research on how best to use this information in a translational context is needed. Given the possible heterogeneity in the magnitude of the association among populations and with environmental factors, a more systematic assessment locus should also be used as a genetic factor with which to investigate both gene-gene and gene-environment interactions with type 2 diabetes.

Supplementary Material
======================

###### \[Appendix, Figure 1 and Tables 1-4\]

BMI

:   body mass index

CI

:   confidence interval

EPIC

:   European Prospective Investigation Into Cancer and Nutrition

HuGE

:   Human Genome Epidemiology

PPARG

:   peroxisome proliferator-activated receptor-γ

SNP

:   single nucleotide polymorphism
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